Kymera IPO Presentation Deck

Lead IRAKIMID Selective for MYD88 Tumors Irrespective of Co-mutations • Lead IRAKIMID degrader is a selective and efficient degrader of both IRAK4 and the IMiD substrates IRAK4 DC50 = 8 nM Ikaros/Aiolos DC5o = 2 nM Degradation leads to cell viability effects preferentially in MYD88- mutant lines irrespective of other mutational status KYMERA - Data support potential for broadly targeting tumors harboring MYD88 mutations Model OCI-LY10 TMD8 SUDHL-2 OC-LY19 U2932 MYD88 L265P mut L265P mut $222R mut Wild type Wild type CD79A/B mut mut Co-mutations TNFAIP3 mut IRF4 mut BCL6 mut mut IRAKIMID (ICM) 0.008 0.022 0.013

View entire presentation